Altogether, these findings highlight that a deeper understanding of the crosstalk between CAFs and tumour cells is crucial to identify key mediators of resistance to CDK4/6 inhibitors toward the development of novel therapeutic strategies. This evidence concerns the gene CDK4 and neoplasm.